Are PE Firms Still Buying Pharmacy Businesses in 2026?

Yes — PE firms are actively buying pharmacy businesses in 2026, with strong appetite for the right profile. Independent pharmacies with $500K+ EBITDA and clean compliance records are fielding competitive offers at 3.6x-7.0x EBITDA. Specialty pharmacy platforms with $1M+ EBITDA are transacting at 9.0x-12.0x EBITDA from PE and strategic buyers building scaled platforms.

Pharmacy PE Activity Quick Facts
Independent pharmacy multiple: 3.6x-7.0x EBITDA | Specialty pharmacy multiple: 9.0x-12.0x EBITDA | Active PE buyers: Ardian, Frazier Healthcare Partners, CapVest, Nautics

Which PE Firms Are Buying Pharmacies in 2026?

The PE firms most active in pharmacy acquisitions in 2026 include Ardian, CapVest, Frazier Healthcare Partners, and Nautics. These firms are building scaled specialty pharmacy platforms through a combination of platform acquisitions and add-on deals. They are not simply buying cash flow — they are acquiring dispensing infrastructure, payer relationships, proprietary compounding capabilities, and clinical service lines that are difficult to replicate organically at speed.

Beyond pure PE, strategic buyers are equally active. PBM-owned specialty pharmacy platforms, integrated health systems expanding into in-house dispensing, and large retail pharmacy chains all have active acquisition programs. Strategic buyers often pay above PE multiples when the target gives them specific capabilities, geographic coverage, or patient populations they cannot easily build themselves. For independent pharmacy owners, the practical implication is that you may receive interest from multiple buyer types simultaneously — and having a broker-managed competitive process is essential to ensuring you see the best offer the market can produce, not just the first one that shows up.

What Kind of Pharmacies Are PE Firms Targeting?

PE buyers in 2026 are targeting pharmacies with three characteristics: margin durability, revenue diversification, and compliance infrastructure. Margin durability means earnings that are not entirely dependent on a single PBM contract at risk of reimbursement compression. Revenue diversification means a mix of specialty dispensing, compounding, clinical services, or long-term care that creates multiple revenue streams beyond retail dispensing. Compliance infrastructure means clean DEA records, up-to-date state licensure, documented SOPs, and financial reporting that can withstand a Quality of Earnings review.

Size matters less than profile. A $600K EBITDA pharmacy with strong specialty dispensing, diverse payer mix, and institutional-grade books will attract more PE interest than a $1.5M EBITDA operation where 80% of margin comes from a single PBM contract up for renewal. Buyers are also paying attention to drug mix — pharmacies with exposure to GLP-1 medications, specialty biologics, and rare disease therapies are commanding premium multiples because those categories carry structural tailwinds independent of reimbursement risk.

"Independent pharmacy owners often underestimate how competitive the buyer market is right now. I have had pharmacy clients receive three or four offers within 60 days of going to market. The ones who capture that competition benefit enormously. The ones who quietly shake hands with the first buyer who calls are usually leaving 15-25% on the table. A structured process with the right preparation makes that difference." — John M. Salony

For the full picture on pharmacy valuations and what drives multiple differences, visit our Pharmacy industry hub. For a related healthcare business perspective, our Dental Practice valuation guide covers another sector with similarly active PE consolidation activity in 2026.

Find Out What Your Pharmacy Business Is Worth

Start with the free valuation calculator on our site — it gives you a range in about two minutes based on your actual numbers. A confidential consultation with John costs nothing and carries zero obligation. We work with pharmacy sellers across Virginia, the Carolinas, Georgia, and Maryland who are evaluating their options now or in the next two to three years.

Frequently Asked Questions

Which PE Firms Are Buying Pharmacies in 2026?
The PE firms most active in pharmacy acquisitions in 2026 include Ardian, CapVest, Frazier Healthcare Partners, and Nautics. These firms are building scaled specialty pharmacy platforms through platform acquisitions and add-on deals. They are not simply buying cash flow — they are acquiring dispensing infrastructure, payer relationships, proprietary compounding capabilities, and clinical service lines that are difficult to replicate organically. Beyond pure PE, strategic buyers are equally active. PBM-owned specialty pharmacy platforms, integrated health systems expanding into in-house dispensing, and large retail pharmacy chains all have active acquisition programs. Strategic buyers often pay above PE multiples when the target gives them specific capabilities, geographic coverage, or patient populations they cannot easily build themselves. For independent pharmacy owners, the practical implication is that you may receive interest from multiple buyer types simultaneously. Having a broker-managed competitive process is essential to ensuring you see the best offer the market can produce, not just the first one that calls. A structured process with the right buyer outreach typically yields 2-4 competing offers for a well-prepared pharmacy with $500K+ EBITDA.
What Kind of Pharmacies Are PE Firms Targeting?
PE buyers in 2026 are targeting pharmacies with three characteristics: margin durability, revenue diversification, and compliance infrastructure. Margin durability means earnings not entirely dependent on a single PBM contract at risk of reimbursement compression. Revenue diversification means a mix of specialty dispensing, compounding, clinical services, or long-term care that creates multiple revenue streams beyond retail. Compliance infrastructure means clean DEA records, up-to-date state licensure, documented SOPs, and financial reporting that can withstand a Quality of Earnings review. Size matters less than profile. A $600K EBITDA pharmacy with strong specialty dispensing, diverse payer mix, and institutional-grade books will attract more PE interest than a $1.5M EBITDA operation where 80% of margin comes from a single PBM contract up for renewal. Drug mix matters too — pharmacies with exposure to GLP-1 medications, specialty biologics, and rare disease therapies are commanding premium multiples because those categories carry structural tailwinds independent of reimbursement risk. The sweet spot for PE buyers is typically $500K-$3M EBITDA with demonstrably durable margins and clean compliance history.